AAH Pharmaceuticals Ltd Sustainability Profile
AAH Pharmaceuticals Ltd, a leading name in the pharmaceutical distribution industry, is headquartered in Great Britain. Established in 1997, the company has grown to become a key player in the supply of healthcare products and services across the UK and Ireland. AAH Pharmaceuticals focuses on delivering a comprehensive range of pharmaceuticals, medical supplies, and healthcare solutions, catering to the needs of pharmacies, hospitals, and healthcare professionals. With a commitment to quality and efficiency, AAH Pharmaceuticals stands out for its robust logistics network and innovative supply chain solutions. The company has achieved significant milestones, including strategic partnerships and expansions that enhance its market position. Recognised for its reliability and customer-centric approach, AAH Pharmaceuticals continues to play a vital role in supporting the healthcare sector, ensuring that essential medicines and products are readily available to those who need them most.
DitchCarbon Score
How does AAH Pharmaceuticals Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AAH Pharmaceuticals Ltd's score of 30 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AAH Pharmaceuticals Ltd's reported carbon emissions
In 2022, AAH Pharmaceuticals Ltd reported total carbon emissions of approximately 22,896,000 kg CO2e. This figure includes about 21,002,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and approximately 1,894,000 kg CO2e from Scope 3 emissions, which encompass indirect emissions from the value chain. Notably, there were no reported Scope 2 emissions for the year. Comparatively, in 2021, the company’s total emissions were about 37,420,370 kg CO2e, with Scope 1 emissions at approximately 32,201,960 kg CO2e, Scope 2 emissions at about 2,681,980 kg CO2e, and Scope 3 emissions at around 2,536,000 kg CO2e. This indicates a significant reduction in total emissions from 2021 to 2022. Despite these reductions, AAH Pharmaceuticals Ltd has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi). The emissions data is cascaded from AAH Pharmaceuticals Ltd as a current subsidiary, reflecting their performance without additional corporate family targets or commitments. Overall, AAH Pharmaceuticals Ltd is making strides in reducing its carbon footprint, particularly in Scope 1 emissions, but lacks formalised climate pledges or reduction targets at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 32,201,960 | 00,000,000 |
| Scope 2 | 2,681,980 | - |
| Scope 3 | 2,536,000 | 0,000,000 |
How Carbon Intensive is AAH Pharmaceuticals Ltd's Industry?
How Carbon Intensive is AAH Pharmaceuticals Ltd's Location?
AAH Pharmaceuticals Ltd's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
AAH Pharmaceuticals Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
